drugset / Trial / NCT06476808

A Study to Evaluate the Safety, Tolerability, and Efficacy of Escalating Doses of BMS-986463 in Participants With Select Advanced Malignant Tumors.

NCT06476808 ↗

Phase 1 Recruiting 240 enrolled Bristol-Myers Squibb
Non-randomizedSequentialOpen-labelTreatment

Summary

The purpose of this study is to evaluate the safety, tolerability, and efficacy of escalating doses of BMS-986463 in participants with select advanced malignant tumors.

Timeline

Start
2024-09-06
Primary completion
2028-12-19
Completion
2028-12-19

Drugs

EvaluationDrugModalityDoseRoute
Subject BMS-986463 Unknown — —